China Cord Blood Corporation (CO) Earning Somewhat Positive Media Coverage, Report Finds
News stories about China Cord Blood Corporation (NYSE:CO) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. China Cord Blood Corporation earned a news impact score of 0.23 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.2257340633811 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- European Union continues to crack down on U.S. companies (finance.yahoo.com)
- Short Interest in China Cord Blood Corporation (CO) Declines By 34.2% (americanbankingnews.com)
- Umbilical Cord Blood Banking Market is Expected to Represent USD 19,335.6 Million By 2020 (medgadget.com)
- China Cord Blood Corp. :CO-US: Earnings Analysis: Q1, 2018 By the Numbers : September 29, 2017 (finance.yahoo.com)
- Is It Time To Sell China Cord Blood Corporation (CO)? (finance.yahoo.com)
China Cord Blood Corporation (CO) traded down 1.29% during midday trading on Thursday, hitting $11.49. 198,428 shares of the stock were exchanged. The company has a market capitalization of $1.30 billion, a P/E ratio of 36.71 and a beta of 0.88. China Cord Blood Corporation has a 1-year low of $4.27 and a 1-year high of $14.95. The company’s 50 day moving average is $12.34 and its 200 day moving average is $9.62.
China Cord Blood Corporation (NYSE:CO) last posted its quarterly earnings data on Wednesday, August 23rd. The medical research company reported $0.09 earnings per share for the quarter. The company had revenue of $33.07 million for the quarter. China Cord Blood Corporation had a net margin of 22.07% and a return on equity of 8.64%. Analysts predict that China Cord Blood Corporation will post $0.15 earnings per share for the current fiscal year.
Separately, BidaskClub upgraded shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 1st.
China Cord Blood Corporation Company Profile
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.